Beyond Buzzwords in Longevity Investing

March 26, 2026 |

1 min read |

Jennifer C. Smith-Parker, BioSpace Insights

In this episode of Denatured, you’ll listen to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We speak about how developers in the longevity space should stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly tackle age-related conditions.

> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music

In this Denatured episode, Jennifer C. Smith-Parker speaks to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We discuss how the goal to increase lifespan in drug development should focus on specific targets that address specific, age-related diseases.

Host

⁠Jennifer C. Smith-Parker⁠, Director of Insights, BioSpace

Guests

Sergey Jakimov, Managing Partner, LongeVC

Artem Trotsyuk, Operating Partner-US, LongeVC

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Podcasts Denatured Clinical research Drug discovery Longevity Venture capital

Jennifer C. Smith-Parker

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

BioSpace Insights

The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.